Invicta Diagnos.
Invicta Diagnos. Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q4 FY26 call signalled
2 of 3 strong
The short version
Invicta Diagnostic targets a threefold increase in the number of diagnostic centers over the next 3 years, which is expected to parallel significant revenue growth. Invicta Diagnostic aims to triple the number of centers in three years, which should drive revenue growth.
From Invicta Diagnos.'s Q4 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Invicta Diagnostic targets a threefold increase in the number of diagnostic centers over the next 3 years, which is expected to parallel significant revenue growth.
- Expansion includes setting up new hub centers (doubling existing hubs) and acquisitions like Vinchurkar Diagnostics to boost operational efficiency and sales.
- The company anticipates newer centers to operationally breakeven within 6-7 months, with revenue contribution beginning thereafter.
- Growth is expected from scaling existing mature centers organically via enhanced machinery capacity and higher patient volumes.
- Tele-radiology and overseas tele-radiology offerings are emerging asset-light verticals contributing to incremental revenue.
2 more points from Invicta Diagnos.'s call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Invicta Diagnos. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Invicta Diagnostic Limited is deploying IPO funds (INR 21 crores raised) primarily towards:
- Purchase of medical equipment.
- Establishment of five new diagnostic centers in Maharashtra.
- Acquisition of Vinchurkar Diagnostics.
- Setting up new centers in Pune and Shegaon.
- Payment for PET-CT machines at the Dadar center.
- The company aims to fully utilize these funds within the current financial year.
- Plans to expand hub centers by setting up four additional hubs, nearly doubling the existing hubs.
- Focus on acquisitions similar to Vinchurkar to improve operational efficiency and increase sales.
2 more points from Invicta Diagnos.'s call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Invicta Diagnos. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Invicta Diagnos.'s call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
Others in Healthcare Services this season
- KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
- Gaudium IVF and Women Health Ltd (Q4 FY26)
Revenue growth seen in FY26: INR 104.35 crore, a 47.56% increase from FY25. Key concall takeaways from Gaudium IVF's Q4 FY26 earnings call — and how it ranks…
- Apollo Hospitals Enterprise Ltd (Q4 FY26)
30% growth currently driven by top 5 markets; expansion planned into new markets. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY26 earnings…
- Health X Platform Ltd (Q4 FY26)
Northeast operations growing 50%+ year-on-year and Northern India 25–30%, with plans for 5–7% market share in 2-3 years (Page 10). Key concall takeaways from…
Arthneeti Pro · Annual
Invicta Diagnos. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Invicta Diagnos. Q4 FY26 results?
Invicta Diagnostic targets a threefold increase in the number of diagnostic centers over the next 3 years, which is expected to parallel significant revenue growth. Invicta Diagnostic aims to triple the number of centers in three years, which should drive revenue growth.
What is Invicta Diagnos. share price analysis?
Invicta Diagnos. currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 19.4 with a market cap of ₹87 Cr. Investors should review the full earnings analysis for detailed insights.
Is Invicta Diagnos. planning capital expenditure?
Invicta Diagnostic Limited is deploying IPO funds (INR 21 crores raised) primarily towards: - Purchase of medical equipment.
Keep Invicta Diagnos. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.